

INDEX

- acceding countries, 25
- Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS). *See also* unfair competition
 - abuse of intellectual property rights, 143
 - anti-competitive licensing practices, 144
 - compulsory licensing, 144
 - IP and competition policy current issues, 144
- anti-competitive practices. *See* unfair competition
- appellations of origin, 90
- Australia – Tobacco Plain Packaging*, 66, 77–80, 195
- beneficiaries, 15–17, 34
- Berne Convention, 12, 34
 - beneficiaries, 16
 - copyright. *See* copyright and related rights
 - enforcement. *See* enforcement
 - exceptions to national treatment and MFN treatment, 17
 - moral rights, 12, 40, 49
 - rule of retroactivity, 26
 - and TRIPS Agreement, 12, 16, 40–2
 - TRIPS Agreement as ‘Berne-plus’, 40
- biodiversity, 216, 226–31. *See also* traditional knowledge and folklore
- biotechnology patenting, 113, 216, 227
- border measures, 157–62
 - procedural requirements and safeguards against abuse, 159–61
- application, including evidence and description of goods, 159
- duration of suspension, 160
- notice of suspension, 160
- posting of security/payment of compensation, 160
- remedies and orders for destruction/disposal, 161–2
- right of inspection and information, 161
- scope and coverage, 157–9
 - mandatory coverage of pirated copyright/counterfeit trademark goods, 157–8
 - optional coverage, 158–9
 - special rules for *ex officio* action, 162
- suspension of release, 14, 157
- broadcasting organizations, related rights, 17, 18. *See also* related rights
- Canada – Pharmaceutical Patents*, 117, 119–20, 178
- Canada – Term of Patent Protection*, 25, 178
- certification marks, 63, 86, 91
- China – Intellectual Property Rights*, 162, 164, 195
- climate change, current TRIPS issues, 237–8
- collective management organizations, 48
- collective marks and certification marks, 63, 86, 91, 94
- competition law and policy. *See* unfair competition

- 'competition law and policy,' meaning of, 142
- compulsory licences
 - developing countries/LDCs
 - educational purposes, 51
 - medicines. *See* TRIPS and public health
 - health
 - emergency situations, 122, 201
 - grounds when normal requirements for compulsory licensing do not apply, 122, 201
 - layout-designs of integrated circuits, 135
 - meaning of, 121
 - medicines and pharmaceuticals. *See* TRIPS and public health
 - no compulsory licensing of trademarks permitted, 81–4
 - patents, 116–17, 121–4
 - applications to be considered on individual merits, 122
 - conditions to be met in case of dependent patents, 123
 - conditions to be respected in the grant of compulsory licences, 121–4
 - decisions on grant/remuneration subject to judicial/independent review, 123
 - licences predominantly for supply of domestic market, 122, 144, 204, 206
 - licences to be non-exclusive, 122
 - remedying anti-competitive practices, 122, 144
 - right holder, adequate remuneration for, 123, 144, 204, 206
 - scope and duration to be limited to purposes for which granted, 122
 - unsuccessful attempt first to obtain a voluntary licence, 122
 - pharmaceutical exports. *See* Paragraph 6 System
 - semi-conductor technology, 135
 - computer programs, 42, 47, 54, 55
 - confidential information. *See* undisclosed information
- Convention on Biological Diversity (CBD), 114
 - and TRIPS Agreement and protecting traditional knowledge/folklore, 114, 216, 220, 229–31, 232
 - current issues, 216, 220, 229–32
- copyright and related rights, 2, 39–57
 - authors' general rights, 46–7
 - beneficiaries, 16
 - Berne Convention and copyright, 39, 40
 - copyright including related or 'neighbouring rights', 40
 - copyright or 'authors' rights', 39
 - definition of, 39–40
 - limitations and exceptions to
 - exclusive rights of authors, 49–53
 - fair use or fair dealing, 50
 - free use, 50
 - minor exceptions, 50
 - non-voluntary licences, 50, 51
 - three-step test, 51
 - pre-existing works and phonograms, 26
 - principles governing eligibility for copyright protection, 44–6
 - automatic protection, 45
 - idea/expression dichotomy, 44
 - independence of protection, 46
 - originality, 45
 - purpose of protection of copyright and related rights, 3, 40
 - related rights. *See* related rights
 - relationship of TRIPS Agreement with Berne and Rome Conventions, 40–2
 - rights to be conferred on
 - authors, 46–9
 - authors' general rights, 46–7
 - economic rights, 46
 - moral rights, 12, 40, 46, 49
 - rental right, 47
 - reproduction right, 47
 - rights of public performance, broadcasting and communication to public, 48

- copyright and related rights (cont.)
 - rights of translation and adaptation, 49
 - subject matter to be protected, 42–6
 - certain other categories of works, 44
 - derivative works, 43
 - literary and artistic works. *See* literary and artistic works
 - principles governing eligibility for copyright protection, 44–6
 - translations and adaptations, 43, 49
 - TRIPS provisions on copyright, 42–54
 - minimum term of protection, 53–4
 - permissible limitations and exceptions, 49–53
 - rights to be conferred on authors, 46–9
 - subject matter to be protected, 42–6
- Copyright Treaty, WIPO, 41, 236
- counterfeiting, copying and piracy. *See also* enforcement
 - border measures, 157–8
 - concerns about counterfeiting and piracy, 146
 - copyright piracy, 54, 146, 148, 155, 157–8, 162
 - definition of, 158
 - counterfeiting, 128, 146
 - international trade in, 148
 - trademark counterfeiting, 148, 154, 155, 157–8, 161, 162
 - definition of, 157
- criminal procedures and penalties, 164. *See also* enforcement
 - remedies, 164
 - scope and coverage, 162
- current TRIPS issues, 32, 35, 216–53
 - climate change, 237–8
 - competition policy, 240–1
 - current issues, 216, 221–37
 - electronic commerce, 217, 236–7
 - geographical indications, 216, 221–6
 - LDCs, 217, 233–5
 - non-violation complaints, 217, 232
 - transfer of technology, 217, 235–6
 - the ‘triplets’: biotech, traditional knowledge and biodiversity, 216, 226–31
 - geographical indications, 216, 221–6
 - background, 221–2
 - higher-level protection for non-wine/spirits products, 218–21, 222, 225–6
 - notification/registration system for GIs for wines/spirits, 218, 221, 222–5
 - innovation, support for, 238–9
 - mandates for work on the TRIPS issues, 218–21
 - bases for ongoing work, 218
 - debate over nature of mandates, 220, 225
 - whether issues should be linked or handled separately, 220
 - non-violation complaints, 217, 232
 - TRIPS Council examining scope and modalities, 217
 - transfer of technology, 235–6
 - the ‘triplets’: biotech, traditional knowledge and biodiversity, 216, 226–31
 - Article 27.3(b) review, 227–8
 - relationship between the TRIPS Agreement and the CBD, 229–31
 - traditional knowledge and folklore, 229–31
- TRIPS Agreement in other
 - multilateral policy processes, 242–53
 - debates on issues outside the WTO, 216–18
 - development issues, 248–50
 - environmental agreements, 251–3
 - human rights, 242–4
 - IP and competition policy, 144, 250–1
 - public health beyond the WTO, 244–8

- databases, 43
- Denmark and Sweden – Measures Affecting the Enforcement of IPRs*, 195
- derivative works, 43
- developed countries
 - assisting developing countries
 - current issues, 235–6
 - monitoring obligations on technology transfer, 235
 - technical cooperation, 27–8, 217, 234
 - assisting LDCs, 24
 - technical cooperation, 27–8, 234
 - technology transfer, 26–7, 203, 217, 233
 - transition periods, 23
- developing countries
 - assistance and technical cooperation
 - from developed countries, 27–8, 217, 234
 - assistance from WIPO/WTO
 - technical cooperation and assistance, 37
 - translation of laws/regulations, 36
 - compulsory licensing, medicines
 - educational purposes, 51
 - medicines. *See* TRIPS and public health
 - copyright, 41
 - current TRIPS issues on
 - development, 248–50
 - Paragraph 6 System. *See also* Paragraph 6 System
 - generic producers, 204, 212
 - re-exporting pharmaceutical products and regional trade agreements, 212
 - review of System's functioning, 214
 - textile design protection, 128
 - transition periods, 23–4
 - TRIPS negotiations, 7
 - outstanding implementation issues, 218
 - dispute prevention and settlement, 13, 166–97
 - clarifications of TRIPS Agreement in dispute settlement, 30
 - description of dispute settlement procedures, 173–7
 - adoption of Panel/Appellate report(s) and implementation, 175–7
 - Appellate review, 175
 - consultations between the parties, 173
 - Panel examination, 174–5
 - retaliation and cross-retaliation, 176
 - dispute prevention and review of national implementing legislation. *See also* TRIPS Council
 - dispute settlement, 168–73
 - general overview of system, 168–71
 - grounds for complaints, 170
 - member governments initiating dispute settlement procedures, 168, 169
 - non-violation and situation
 - complaints, 171–3
 - private parties, 169
 - and review of national implementing legislation, 167–8
 - third parties, 169, 173
 - violation complaints, 170
 - Dispute Settlement Body (DSB), 170, 174, 176
 - DSU, 10, 169
 - exhaustion of IPRs, 21, 202
 - general statements, 200
 - guide to resources, 195–7
 - non-violation and situation
 - complaints, 171–3
 - current issues, 217, 232
 - moratorium on application of complaints, 8, 170, 172
 - TRIPS Council examining scope and modalities, 172, 217
 - and objectives/principles of TRIPS Agreement, 14
 - as TRIPS Agreement key feature, 166
 - TRIPS-related cases, 177–97

- distinctive signs, 61–3. *See also*
 - geographical indications (GIs); trademarks
- Doha Declaration on the TRIPS Agreement and Public Health, 21, 35, 198, 216, 236
 - clarification of flexibilities, 201–2
 - compulsory licences, 121, 122, 201
 - concerns that triggered discussions, 199–200
 - emergency situations, 122, 201
 - follow-up, 203
 - general statements, 200–1
 - interpreting TRIPS Agreement, 14
 - LDCs and pharmaceutical product patents, 24, 233
 - scope of application, 200
 - transfer of technology, 203
- Doha Development Agenda, 10, 218
- Doha Ministerial Declaration, 21, 32, 35, 100, 114
 - current TRIPS issues, 218–21, 222, 226
- EC – Bananas III*, 177
- EC – Trademarks and Geographical Indications*, 81–3, 178
- electronic commerce, 217, 236–7
 - complexity of IP issues, 236
 - no customs duties on electronic transmissions, 236
 - TRIPS Council, 237
- enforcement, 13, 146–65
 - application of basic principles, 148
 - background, 146
 - border measures. *See* border measures
 - civil and administrative procedures and remedies, 151–5
 - evidence, 151, 152, 155, 159
 - fair and equitable procedures, 150, 151
 - cooperation and contact points
 - contact points, 165
 - cooperation between members, 165
 - current issues, 217
 - decisions on merits of case, 151
 - effects of infringement, 147
 - general obligations, 149–51
 - basic principles of due process, 151
 - indemnification of defendant, 154–5, 156, 160
 - IPR enforcement described, 147–8
 - relationship of TRIPS Agreement with other pre-existing treaty provisions, 146, 149
 - remedies, 152–4
 - damages, 153–4
 - injunctions, 153, 155
 - other remedies and orders for destruction/removal, 154
 - right of appeal, 151
 - right of information, 154
- environmental agreements, 251–3
- EU trademarks, 72–4
- European Communities and Portugal – Enforcement of IPRs in Motion Pictures and Television Programs*, 195
- exclusive rights, 1, 178
 - developing countries/economies in transition and exclusive marketing rights, 24
 - LDCs and marketing rights, 24, 31, 203
- exhaustion, 20
 - international exhaustion regimes, 20, 202
 - layout-designs of integrated circuits, 135
 - meaning of, 20
 - national exhaustion regimes, 20, 202
 - and parallel importation, 20
 - regional exhaustion regimes, 21
- free riding. *See* unfair competition
- General Agreement on Tariffs and Trade (GATT)
 - GATT (1947), 4, 5
 - GATT (1994), 5, 167, 169
 - Tokyo Round, 6, 146
 - Uruguay Round, 5, 218
 - counterfeit goods, 146, 148

- TRIPS negotiations, 14, 21, 40, 60, 85, 98
- general provisions and basic principles of TRIPS Agreement, 14
- beneficiaries, 15–17
- exhaustion. *See* exhaustion
- minimum standards agreement, 15
- national/MFN treatment. *See* national treatment and MFN treatment
- objectives and principles, 14
- generic producers, 204, 212
- geographical indications (GIs), 2, 85–104
 - additional protection for GIs for wines and spirits (Article 23), 98–101
 - homonymous GIs for wines (Article 23.3), 100
 - negotiation of a multilateral register of GIs for wines (Article 23.4), 100
 - protection against use as a trademark (Article 23.2), 100
 - protection against use by others (Article 23.1), 99
- background, 85–6
- collective marks, 63, 91, 94
- current issues, 216, 221–6
 - background, 221–2
 - higher-level protection for products other than wine/spirits, 218, 225–6
- notification/registration system for GIs for wines/spirits, 218, 221, 222–5
- definition of, 85, 87
- elements of Article 22.1 definition 78–80
 - function of identification, 88
 - geographical origin identified by GI, 88
 - quality, reputation or other characteristics due to geographical origin, 89
 - subject matter of identification, 88
- exceptions, 101–4
 - generic terms (Article 24.6), 101
 - GIs not protected in country of origin/fallen into disuse (Article 24.9), 103
 - prior trademark rights (Article 24.5), 102
 - prior use of GI (Article 24.4), 102
 - time limit to challenge trademarks under Articles 22.3 and 23.2 (Article 24.7), 103
 - use by a person of his name (Article 24.8), 103
- GIs, indications of source, rules and appellations of origin, trademarks
 - geographical indications and appellations of origin, 90
 - geographical indications and indications of source, 90
 - geographical indications and rules of origin, 90
 - geographical indications, trademarks and certification marks, 91
- indefinite protection, 2
- indications of source, rules and appellations of origin, trademarks, 89–94
- international negotiations, review and standstill, 104
 - international negotiations (Article 24.1), 104
 - standstill (Article 24.3), 104
- notification/registration system for GIs for wines/spirits, 218, 221, 222–5
- and Paris Convention, 85, 86
 - relationship of TRIPS Agreement with pre-existing provisions, 86
- protection and rights conferred for geographical indications for all goods, 95–101
 - factually true but misleading use (Article 22.4), 98
 - protection against use by others (Article 22.2), 95–7
 - protection against uses as a trademark (Article 22.3), 97
- purposes of GI protection, 4

- geographical indications (GIs) (cont.)
 - subject matter to be protected 78–84
 - definition of, 85
 - definition of GIs, 87
 - elements of Article 22.1
 - definition, 87–9
 - examples of GIs and logos or symbols, 92–4
 - indications of source, rules and appellations of origin, trademarks, 89–94
 - right holders and eligible users, 91
 - trademarks, 70
 - TRIPS provisions on geographical indications, 87–104
 - conditions for getting protection, 94
 - subject matter to be protected, 87–91
- Handbook on the WTO Dispute Settlement System* (WTO Secretariat), 196
- health
 - public health. *See* TRIPS Agreement and public health
- historical and legal background to TRIPS, 4–8
 - TRIPS negotiations, 6–8
- human rights and the TRIPS Agreement, 242–4
- India – Patents I and II*, 24, 178
- indigenous peoples
 - traditional knowledge and folklore. *See* traditional knowledge and folklore
- industrial designs, 2, 44, 126–30
 - definition of, 127
 - general formalities for protection, 128
 - general formalities for protection of industrial designs
 - formalities, 128
 - priority, 128
 - minimum term of protection, 130
 - permitted exceptions to rights conferred, 130
 - rights to be conferred, 129–30
 - rights to be conferred on owners of a protected industrial design, protection not including forfeiture, 129
 - subject matter to be protected, 127–9
 - general formalities for protection, 128
 - protection for new or original designs and independently created designs, 127
 - textile designs, 128–9
- industrial property, 2, 44
 - beneficiaries, 15
 - distinctive signs. *See* geographical indications (GIs); trademarks
 - inventions/new technologies. *See* industrial designs; patents
- innovation
 - current issues in support for, 238–9
 - recognizing and stimulating, 3, 14, 106
- institutional arrangements, 13, 28–38
 - Council for TRIPS. *See* TRIPS Council
 - WTO Agreement. *See* World Trade Organization (WTO)
- integrated circuits. *See* layout-designs (topographies) of integrated circuits
- intellectual property (IP) system
 - intellectual property rights. *See* intellectual property rights (IPRs)
 - public policy tool, 3–4
- Intellectual Property in Respect of Integrated Circuits (IPIC) Treaty, 12, 22, 131
 - beneficiaries, 15
 - layout-designs. *See* layout-designs (topographies) of integrated circuits
 - national treatment and MFN treatment, 17, 18
- intellectual property rights (IPRs), 1–3
 - acquisition and maintenance of IPRs, 13, 22

- copyright. *See* copyright and related rights
 current TRIPS issues as to
 competition policy, 250–1
 enforcement. *See* enforcement
 exclusive rights. *See* exclusive rights
 industrial property. *See* industrial property
 nature of, 1
 and public interest, 240
 standards for availability, scope and use of, 11–12
 territorial rights, 2, 60
 International Union for the Protection of New Plant Varieties (UPOV Convention), 113
 Internet, 236
 WIPO Internet treaties, 41
Japan – Measures Concerning Sound Recordings, 26, 178
 layout-designs (topographies) of
 integrated circuits, 131–5
 definition of, 131–2
 limitations and exceptions to rights conferred, 133–5
 compulsory licensing, 135
 exhaustion, 135
 innocent infringement, 134
 parallel creation, 134
 reproduction for private or research purposes, 133
 minimum term of protection, 135
 rights to be conferred, 133
 subject matter to be protected, 132–3
 originality and not commonplace requirements, 132
 least-developed countries (LDCs). *See also* developing countries
 assistance and technical cooperation
 Joint Initiative on Technical Cooperation for Least-Developed Countries, 234
 Swedish International Development Cooperation Agency report (2013), 234
 from WIPO/WTO, 37, 234
 assistance and technology transfer
 from developed countries, 24
 technical cooperation, 27–8, 234
 technology transfer, 26–7, 203, 217, 233, 235–6
 compulsory licensing, current TRIPS issues, 233–5
 helping LDCs to implement TRIPS, 234
 Paragraph 6 System, 208
 deemed insufficient or no manufacturing capacity, 209
 re-exporting and regional trade agreements, 212
 transition periods, 24–5, 233
 extension for pharmaceutical products, 31, 203, 233
 waiver of obligations concerning exclusive marketing rights, 24, 31, 203
 licences. *See* anti-competitive practices in contractual licences, control of; compulsory licences
 literary and artistic works, 42–3
 computer programs, 42
 databases, 43
 Madrid Agreement and Madrid Protocol, 19, 94
 Marrakesh Agreement, 5, 8, 55, 169
 medicines and pharmaceutical products. *See* TRIPS and public health
 MFN treatment. *See* national treatment and MFN treatment
 minimum standards agreement, 15
 moral rights, 12, 40, 49
 Multilateral Trade Organization, 8
 national law, 15, 32
 anti-competitive practices, 142
 competition law and policy. *See* competition law and policy
 copyright, 39, 44
 limitations and exceptions. *See* copyright and related rights

- national law (cont.)
 - differences in national legal systems
 - to be taken into account, 147, 148
 - enforcement, 147, 148
 - GIs, 86, 88, 94, 96, 98, 104
 - industrial designs, 127, 129
 - layout-designs of integrated circuits, 132
 - monitoring of members' compliance with obligations. *See* TRIPS Council
 - notifications. *See* notifications
 - official texts, 44
 - patents, 105, 111, 113, 226
 - public health, 198, 200, 201, 205, 213
 - publication of laws, regulations and judicial decisions, 167
 - related rights, 55
 - review of national laws and regulations. *See* TRIPS Council
 - supply of information on laws and judicial decisions to other Members, 168
 - trademarks, 58, 63, 64, 66, 71, 76
 - permissible exceptions. *See* trademarks
- national treatment and MFN
 - treatment, 17–19, 21, 23
 - enforcement procedures and remedies, 148
 - exceptions, 17, 18–19
 - GIs, 85
 - MFN, 17, 18–19, 34
 - national treatment, 17–19, 34
- exceptions nationality, 15, 16
- non-discrimination. *See* national treatment and MFN treatment
- non-violation. *See* dispute prevention and settlement
- notifications, 33–4, 167
 - cooperation between WTO and WIPO, 36–8
 - Paragraph 6 System, 209–10
 - review of national laws and regulations, 35
- objectives and principles of TRIPS Agreement, 14
- ordre public*. *See* security interests
- Pakistan – Patent Protection for Pharmaceutical and Agricultural Chemical Products*, 178
- Paragraph 6 System, 204–15
 - Chairman's statement, 212–13
 - description of, 205–12
 - avoidance of double remuneration, 211
 - eligible importing members, 208
 - exporting members, 209
 - notifications, 209–10
 - regional trade agreements as special cases, 211–12
 - safeguards against diversion, 210–11
 - scope and coverage, 208
 - establishment of, 203, 204–5
 - legal basis of, 206
 - national implementing legislation, 213
 - in a nutshell, 207–8
 - reason for, 204
 - review of functioning of, 214–15
 - use of, 214
- parallel imports, 20, 158, 202
- Paris Convention, 12, 22, 40
 - beneficiaries, 15
 - enforcement, 146
 - GIs. *See* geographical indications (GIs)
 - national emblem protection, 37, 70
 - national treatment and MFN, 17
 - patents. *See* patents
 - trademarks. *See* trademarks
 - and TRIPS Agreement, 12, 15, 60, 86, 106
 - unfair competition, 136
- patents, 2, 105–25. *See also* industrial designs
 - conditions inventions must meet to be eligible for patent protection, 108–14
 - 'best mode' requirement, 110

- formal conditions, 105, 108, 111
- non-discrimination, 111, 116–17, 120
- novelty, inventive step and industrial applicability, 108–10
- permissible exclusions from patentable subject matter, 111–13
- priority, 110
- relationship between TRIPS Agreement/CBD/traditional knowledge, 114
- review of Article 27.3(b), 113, 226
- substantive conditions, 108
- current issues, 216, 226–31
 - Article 27.3(b) review, 227–8
 - relationship between TRIPS Agreement and CBD, 229–31
 - traditional knowledge and folklore, 228–9
- definition of, 105–6
- dependent patents, 123
- developing countries and transitional arrangements, 23–4
- exceptions that WTO members can allow to patent rights, 117–24
 - compulsory licences
 - compulsory licences
 - limited exceptions, 118–20
- fees, 124
- ‘invention,’ definition of, 105
- LDCs and transitional arrangements, 24–5, 203
- medicines and pharmaceutical products. *See* TRIPS and public health
- minimum period of protection to be accorded, 124
 - term of protection, 2, 124
- novelty, inventive step and industrial applicability, 108–10
- industrial applicability/utility, 109, 112
- inventive step/non-obviousness, 109
- novelty, 108
- permissible exclusions from patentable subject matter, 111–13
 - methods of treatment, 112
 - ordre public* or morality, 112
 - plants and animals, 113, 226
- prior art, 23, 108, 109, 110
- process patents, rights to be conferred on owners of, 115–16
 - burden of proof, 115–16
 - rights of process patent owners, 115–16
- purposes of patent protection, 4, 14, 106, 110
- relationship of TRIPS Agreement with Paris Convention pre-existing provisions, 106
- revocation, 125–5
- rights to be conferred on patent owners, 114–17
 - assignment, transfer and licensing of patents, 117
 - non-discrimination with respect to availability and enjoyment of patent rights, 111, 116–17, 120
 - other rights of patent owners, 117
 - rights to be conferred on owners of process patents, 115–16
 - rights to be conferred on owners of product patents, 115
- subject matter to be protected by patents, 107–14
 - areas in which inventions must be eligible for protection, 107
 - conditions inventions must meet to be eligible for patent protection, 108–14
- three-step test, 118
- traditional knowledge and folklore, 114, 228–9
- TRIPS provisions on patents, 106–25
 - exceptions that WTO members can allow to patent rights, 117–24
 - minimum period of protection to be accorded, 124
 - rights to be conferred on patent owners, 114–17
 - subject matter to be protected by patents, 107–14
 - waiver of members’ obligations, 31

- Performances and Phonograms Treaty, WIPO, 41, 236
- performers. *See* related rights
- pharmaceutical exports, compulsory licencing system. *See* Paragraph 6 System
- pharmaceutical products. *See* TRIPS and public health
- phonogram producers. *See* related rights
- phonogram producers, related rights, 16, 18
- piracy. *See* counterfeiting, copying and piracy
- plant new varieties
- protection for, 113
- review of Article 27.3(b), 113
- prior art, 23, 108, 109, 110
- provisional measures, 155–6
- procedural requirements and safeguards against abuse, 156
- why and what type of, 155–6
- public goods, 3
- public health. *See* TRIPS and public health
- related rights, 2, 39–40. *See also*
- copyright and related rights
- broadcasting organizations, 17, 54, 56
- national treatment, 18
- performers, 16, 54, 55, 56
- national treatment, 18
- protection of existing subject matter, 26
- phonogram producers, 16, 26, 54, 55, 56
- national treatment, 18
- protection of existing subject matter, 26
- purpose of protection of copyright and related rights, 3, 40
- and Rome Convention, 12, 39, 41, 54, 56
- TRIPS provisions on related rights, 54–7
- copyright, 55–6
- limitations and exceptions, 56
- minimum term of protection, 56
- Rome Convention, 12, 34
- broadcasting organizations, 17, 41
- national treatment and MFN treatment, 17
- performers, 16, 41
- phonogram producers, 16, 41
- related rights. *See* related rights and TRIPS Agreement, 16, 40–2
- security interests, 28
- compulsory licensing, 122
- ordre public*, 112
- special compulsory licencing system for pharmaceutical exports. *See* Paragraph 6 System
- spirits, protection for. *See* geographical indications (GIs)
- Swedish International Development Cooperation Agency, 234
- technology transfer and dissemination
- current issues, 217, 235–6
- Doha Declaration, 203
- electronic commerce, 236
- LDCs. *See* least-developed countries (LDCs)
- objective of IP protection, 4, 14, 26
- transitional arrangements, 26–7
- textile designs, 128–9, 147
- trade names, 63
- Trade Negotiations Committee, 10, 219, 220, 224, 226, 231
- Trade Policy Review Mechanism, 10, 33
- trade secrets. *See* undisclosed information
- trademarks, 2, 58–84
- conditions for registration as a trademark, 64–70
- priority, 64
- publishing requirement, 64
- reasons which may constitute grounds for refusal of registrations, 67
- reasons which may not constitute grounds for refusal of registrations, 65–7

- reasons which must constitute grounds for refusal of registrations, 70
- EU trademarks, 72–4
- indefinite protection, 2, 84
- on the Internet, 236
- and Paris Convention, 58, 59, 60
 - relationship of TRIPS Agreement with pre-existing provisions, 60
- permissible exceptions to trademark rights, 81–4
 - no compulsory licensing permitted, 81–4
 - permitted exceptions, 81–3
- purposes of trademark protection, 4, 59
- reasons which may not constitute grounds for refusal of registrations, 65–7
 - actual use of trademark at time of registration, 67
 - failure to register in country of origin/independence of protection, 65
 - form of mark, if already registered in other member countries, 65–6
 - nature of goods/services identified by trademark, 66–7
- reasons which must constitute grounds for refusal of registrations, 70
- geographical indications, 70, 97, 100
- state emblems and official hallmarks, 37, 70
- well-known marks, 70
- rights to be conferred on trademark owners, 71–80
 - general rights, 71
 - licensing and assignment of rights, 76
 - rights with respect to well-known trademarks, 74–6
 - trademark rights, 71–4
 - ‘twinning’ requirements, 77–80
- role of trademarks, 58–60
 - acquisition of trademark rights, 60
 - protection of service marks as well as trademarks for goods, 59
 - trademarks with respect to certain products, 59
- subject matter of trademark protection, 61–4
 - collective marks and certification marks, 63, 91, 94
 - distinctive signs, 61–3
 - trade names, 63
- trademark rights, 71–4
- TRIPS provisions on trademarks, 61–84
 - permissible exceptions to trademark rights, 81–4
 - rights to be conferred on trademark owners, 71–80
 - subject matter to be protected and conditions for registration, 61–70
 - term of protection, 2, 84
 - well-known trademarks, 70, 74–6
 - WIPO treaties on registration, 60
- traditional knowledge and folklore
 - CBD, 114, 229–31
 - current issues, 228–9
 - patents, 114, 228–9
 - WIPO Intergovernmental Committee on IP and Genetic Resources, Traditional Knowledge and Folklore, 229
- transfer of technology. *See* technology transfer and dissemination
- transitional arrangements and other matters, 13, 22–8
- protection of existing subject matter, 25–6
 - additional requirements in respect of pre-existing works and phonograms, 26
 - application of rules, 25
 - security exceptions, 28
 - technical cooperation, 27–8
- transfer of technology. *See* technology transfer and dissemination
- transition periods, 8, 22–5
 - acceding countries, 25

- transitional arrangements (cont.)
 - developed countries and non-discrimination, 23
 - developing countries and economies in transition, 23–4
 - LDCs, 24–5, 203, 233
- Treaty on Intellectual Property in Respect of Integrated Circuits. *See* IPIC Treaty
- TRIPS Agreement
 - amending, 31
 - current TRIPS issues. *See* current TRIPS issues
 - dispute prevention and settlement. *See* dispute prevention and settlement
 - enforcement. *See* enforcement
 - exceptions to national treatment and MFN treatment, 18
 - general provisions. *See* general provisions and basic principles of TRIPS Agreement
 - historical and legal background to TRIPS, 4–8, 17
 - and human rights. *See* human rights and the TRIPS Agreement
 - intellectual property rights. *See* intellectual property rights (IPRs)
 - and other Conventions. *See* Berne Convention; Convention on Biological Diversity (CBD); Paris Convention; Rome Convention
 - overview of TRIPS provisions, 10–13
 - place of TRIPS in the WTO, 8–10
 - TRIPS Agreement administered by TRIPS Council. *See* TRIPS Council
 - and public health. *See* TRIPS Agreement and public health
 - transitional arrangements. *See* transitional arrangements and other matters
 - TRIPS Agreement as integral part of WTO Agreement, 8
 - waiver of members' obligations, 31
- TRIPS Agreement and public health, 198–215
 - access to medicines, broader picture of, 198, 216, 244–8
 - balancing incentives for research/development and accessibility to drugs, 198, 201
 - 'Bolar' provision, 118
 - compulsory licences for medicines/pharmaceutical products, 121
 - emergency situations/public health crises, 122, 201
 - export to countries lacking domestic manufacturing capacity, 122, 204, 208, 209
 - members free to decide grounds on which licences granted, 201
 - Paragraph 6 System. *See* Paragraph 6 System
 - right holder, adequate remuneration for, 123, 204, 206
 - current TRIPS issues, 244–8
- Doha Declaration. *See* Doha Declaration on the TRIPS Agreement and Public Health
- undisclosed test and other data, 138–40
- waiver decisions, 24, 31, 203, 204–5
 - amendment to the TRIPS Agreement, 31
- TRIPS Council, 32–8
 - administering TRIPS Agreement, 8, 10, 32
 - consultations, 35
 - current TRIPS issues. *See* current TRIPS issues
 - electronic commerce, 237
 - forum for further negotiation or review, 35–6
 - GIs, 104
 - monitoring members' compliance with obligations, 167–8
 - non-violation and situation complaints, scope and modalities of, 172, 217
 - notifications, 33–4
 - public health, further work on, 203

- review of Paragraph 6 System's functioning, 214–15
 - review of national laws and regulations, 35, 167–8, 177
 - WTO and WIPO cooperation, 25, 36–8
- Understanding on Rules and Procedures Governing the Settlement of Disputes (DSU). *See* dispute prevention and settlement
- undisclosed information, 136–45
 - trade secrets and confidential information, 2, 137–8
 - information made subject to reasonable steps to keep it secret, 138
 - information that has commercial value because it is secret, 137
 - information that is secret, 137
 - length of protection, 2, 138
 - protecting trade secrets in enforcement proceedings, 152
- undisclosed test and other data, 138–40
- unfair competition, 2, 87, 96, 136, 140–2
 - anti-competitive practices control generally, 142–3
 - TRIPS provisions, 143–5
 - current TRIPS issues as to competition law, 240–1
 - free riding, 59, 96
- United Nations Conference on Trade and Development (UNCTAD), 234
- Uruguay Round. *See* General Agreement on Tariffs and Trade (GATT)
- US – *Gambling*, 177
- US – *Section 110(5) Copyright Act*, 41, 48, 50, 51–3, 178
 - summary of key Panel finding, 52–3
- US – *Section 211 Omnibus Appropriations Act*, 66, 68, 195
- US – *Upland Cotton*, 177
- utility models, 2, 132
- waiver of members' obligations under TRIPS Agreement, 31
 - and public health. *See* TRIPS and public health
- well-known trademarks, 70, 74–6
- wines and spirits, protection for. *See* geographical indications (GIs)
- World Health Organization (WHO), 28
 - cooperation with WIPO and WTO, 234
- World Intellectual Property Organization (WIPO), 12, 28, 105, 195
 - cooperation with WHO and WTO, 234
 - cooperation with WTO. *See* World Trade Organization (WTO)
- Copyright Treaty, 41, 236
- electronic commerce, 236
- Intergovernmental Committee on IP and Genetic Resources, Traditional Knowledge and Folklore, 229
- Performances and Phonograms Treaty, 41, 236
- trademarks. *See* trademarks
- World Trade Organization (WTO), 4
 - cooperation with UNCTAD, 234
 - cooperation with WHO and WIPO, 234
 - cooperation with WIPO, 36–8, 234
 - Joint Initiative on Technical Cooperation for Least-Developed Countries, 234
 - Council for Trade in Goods, 10
 - Council for Trade in Services, 10
 - Dispute Settlement Body (DSB), 10
 - forum for negotiations among members, 35–6
- GATT. *See* General Agreement on Tariffs and Trade (GATT)
- General Council, 10, 172
 - decision-making procedures, 29–32
- IP and competition policy current issues, 144
- Ministerial Conference, 10, 172

World Trade Organization (cont.)	amendment of multilateral trade
decision-making procedures,	agreements, 31, 205
29–32	authoritative interpretations, 29
non-discrimination as key	decision-making procedures, 29–32
principle, 17	scope of WTO Agreement, 28
Trade Negotiations Committee, 10,	Trade Policy Review Mechanism
219, 220, 224, 226, 231	8–9, 33
TRIPS. <i>See</i> TRIPS Agreement	voting and consensus, 29
WTO Agreement, 5, 8, 10, 28–32,	waiver of members’ obligations, 31
169	<i>WTO Analytical Index</i> , 196